On 25 November, 2020, Zhejiang East Asia Pharmaceutical Co., Ltd. ("East Asia") (stock code: 605177) successfully listed on the main board of the Shanghai Stock Exchange. Llinks acts as East Asia's legal counsel to provide legal services for this Listing.
Since its establishment in 1998, East Asia has focused on research and development, production and sales of bulk pharmaceutical chemicals and intermediates. The company's products mainly cover the following fields: antibacterial (β-Lactam and Quinolones), anticholine and synthetic spasmolytic (Trimebutine Maleate), antifungal, etc. With the advantage of its products, East Asia has established stable strategic cooperation with many well-known pharmaceutical enterprises at home and abroad. Also, relying on its advantages in research and development, business channels, advanced synthetic technology, complete production system and strong production capacity, East Asia has developed into a modern chemical active pharmaceutical ingredient manufacturing enterprise with complete equipment, superb technology, strong industrialization capacity and formal quality control standards.
Entrepreneur's Message: Llinks Law Offices is a trustworthy partner with pragmatic legal team. In the process of East Asia's listing, the team have showed their strong professional ability. I believe that there will be more cooperation between East Asia and Llinks in the future.
--Mr. Zhengming Chi, CEO of East Asia
